Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARQ 197 plus erlotinib versus placebo plus erlotinib in previously treated advanced non-squamous NSCLC
NL-OMON36396Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ARQ 197 plus erlotinib with Placebo plus erlotinib (2 arms). Primary endpoint: Overall survival in the intent-to-treat population. Planned start May 2011; status: not yet recruiting.
02
Drugs
tivantiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON36396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36396.